Cancer is a disease of the genome, and it is characterized by a genomic instability in which numerous point mutations accumulate and structural alterations occur in the process of tumor progression.
Increasing Number Of TIGIT Inhibitors Drug In Clinical Trials Shows The Promising Future For The Therapy Says Kuick Research
TIGIT Inhibitor Clinical Trials Intelligence Report Insight:
- Number of TIGIT Inhibitor Drug In Trials
- TIGIT Inhibitors Trials By Phase, Company, Country, Indication
- Granted Patent Insight
- Clinical Trials Adverse Events Scenario
- Available Financing Information for TIGIT Trials
- Company Agreement/Partnership/Deals For Ongoing Trials
For Report Sample Contact neeraj@kuickresearch.com
Cancer is a disease of the genome, and it is characterized by a genomic instability in which numerous point mutations accumulate and structural alterations occur in the process of tumor progression. Such genomic variations leads to tumor antigens which can be recognized by immune system as foreign and elicit immune response. Until recently, chemotherapy, radiation, and surgery were considered the cornerstones of cancer treatment. However, the paramount achievement in cancer treatment in last few years has undoubtedly seen introduction of large number of immunotherapeutic approaches in the treatment of cancer.
The advent of immune checkpoint inhibitors in the market represents one of the most promising immunotherapeutic class. In just a few years, PD1/PDL1 immune checkpoint inhibitors have transformed the treatment of multiple cancers, and the leading products from Merck and Bristol Myers Squibb have become mega-blockbusters. Despite their encouraging response, several patients does not respond to their therapies. Therefore, the key area of focus of pharmaceutical companies is to identify other therapies could complement PD1/PDL1 inhibitors or reach patient populations that do not respond well to them.
The genomic analysis have recently identified TIGIT (T-cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domains), which is a novel negative immune checkpoint, expressed on T cells and NK cells. The TIGIT has emerged out to be key inhibitor of anti-tumor responses that can hinder multiple stages of the cancer immune cycle. The precise mechanism of action remains unclear and may have both cell-intrinsic and cell-extrinsic components; it can, for example, prevent NK from releasing tumor antigens cells, alter the priming of T cells by DCs or inhibit the killing of cancer cells by CD8+ T cells.
The diverse function of TIGIT in multiple cancer types has gained considerable interest by researchers. Owing to its conferred advantages, an increasing number of candidates being studied in preclinical and clinical settings. Preclinical studies have indicated that TIGIT blockade can protect against various solid and hematological cancers. Several monoclonal antibodies have been developed that block the inhibitory activity of human TIGIT. Studies combining antibodies against TIGIT with ICI of the PD-1 / PD-L1 pathway have become particularly interesting in light of the data showing the co-expression of TIGIT and PD-L1 in many types of cancer. Clinical trials are underway studying TIGIT blockade alone or in combination with PD1 / PD-L1 antibodies for the treatment of patients with advanced solid tumors.
As per our analysis, there are currently more than 30 ongoing clinical trials which are evaluating around 15 potential candidates in wide range of cancers. Tiragolumab developed by Roche is the first anti-TIGIT antibody which has been granted Breakthrough Therapy designation. It is expected that the novel therapy will enter the market by 2023 and will shown high adoption rates owing to its enhanced specificity and efficacy towards cancer treatment. The restless investments by pharmaceutical giants and encouraging clinical data suggests that these novel drug class will revolutionize the management of cancer and will hold a considerable segment in cancer therapeutic market. The TIGIT inhibitor market is competitive and pharmaceutical giants are increasingly entering into collaboration or acquisitions which will drive this segment during the forecast period.
Surge in prevalence of cancer across geographies and increase in awareness of immune checkpoint inhibitors drive the growth of the global TIGIT inhibitors market. Furthermore, technological advancements in screening procedure for cancer, increased healthcare expenditures, increase in government initiatives to alleviate cancer, and rise in public awareness are expected to boost the growth of the market. Furthermore, about 20 clinical trials are ongoing in US, which wil boost the regional market. Keeping in mind, the high adoption rates, presence of large pharmaceutical giants, and rising geriatric population; it is expected that US will remain at front foot in the global TIGIT inhibitor market during the forecast period.
Contact:
Neeraj Chawla
Research Head
+919810410366